4.8 Article

Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 129, Issue 2, Pages 759-773

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI123557

Keywords

-

Funding

  1. National Key Research and Development Program of China [2017YFA0505500]
  2. Chinese Academy of Sciences [QYZDB-SSW-SMC052]
  3. Strategic Priority Research Program of the Chinese Academy of Sciences [XDB19000000, XDA12000000]
  4. National Natural Science Foundation of China Distinguished Young Scholars Program [81825018]
  5. National Natural Science Foundation of China [31471281, 81773121, 81802818, 81772723, 81830054, 81572536, 81772742, 81672850]
  6. MOHRSS
  7. National Postdoc Management Committee [bx201800247]

Ask authors/readers for more resources

Loss of phosphatase and tensin homolog (PTEN) represents one hallmark of prostate cancer (PCa). However, restoration of PTEN or inhibition of the activated PI3K/AKT pathway has shown limited success, prompting us to identify obligate targets for disease intervention. We hypothesized that PTEN loss might expose cells to unique epigenetic vulnerabilities. Here, we identified a synthetic lethal relationship between PTEN and Brahma-related gene 1 (BRG1), an ATPase subunit of the SWI/SNF chromatin remodeling complex. Higher BRG1 expression in tumors with low PTEN expression was associated with a worse clinical outcome. Genetically engineered mice (GEMs) and organoid assays confirmed that ablation of PTEN sensitized the cells to BRG1 depletion. Mechanistically, PTEN loss stabilized BRG1 protein through the inhibition of the AKT/GSK3 beta/FBXW7 axis. Increased BRG1 expression in PTEN-deficient PCa cells led to chromatin remodeling into configurations that drove a protumorigenic transcriptome, causing cells to become further addicted to BRG1. Furthermore, we showed in preclinical models that BRG1 antagonist selectively inhibited the progression of PTEN-deficient prostate tumors. Together, our results highlight the synthetic lethal relationship between PTEN and BRG1 and support targeting BRG1 as an effective approach to the treatment of PTEN-deficient PCa.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available